UB Paderborn / Katalog / Suche / in CDI

Extramedullary multiple myeloma escapes the effect of thalidomide

Haematologica (Roma), 2004-07, Vol.89 (7), p.832

2004

Volltextzugriff (PDF)

Bortezomib: A valuable new antineoplastic strategy in multiple myeloma

Acta oncologica, 2005, Vol.44 (5), p.440-448

2005

Volltextzugriff (PDF)

Response to thalidomide in multiple myeloma: impact of angiogenic factors

Cytokine (Philadelphia, Pa.), 2004-05, Vol.26 (4), p.145-148

2004

Volltextzugriff (PDF)

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Blood, 2018-11, Vol.132 (Supplement 1), p.5573-5573

2018

Volltextzugriff (PDF)

P-124: The history of survival improvement in patients with Multiple Myeloma through real-world data in a 45-year period at a single institution

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S102-S102

2021

Volltextzugriff (PDF)

P-179: Immunoparesis remains a negative prognostic factor in newly diagnosed Multiple Myeloma by competing risk analysis

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S135-S135

2021

Volltextzugriff (PDF)

P-169: Outcome of non-transplant eligible patients with newly diagnosed multiple myeloma depending on the eligibility for clinical trials: a single institution experience

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S128-S129

2021

Volltextzugriff (PDF)

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p

Clinical lymphoma, myeloma and leukemia, 2018-11, Vol.18 (11), p.e493-e499

2018

Volltextzugriff (PDF)

Bortezomib: an effective agent in extramedullary disease in multiple myeloma

European journal of haematology, 2006-05, Vol.76 (5), p.405-408

2006

Volltextzugriff (PDF)

P-032: Clinical characteristics and outcome of 30 patients with poems syndrome in Catalonia: impact of autologous stem cell transplantation in first line and at relapse

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S55-S56

2021

Volltextzugriff (PDF)

OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S24-S25

2021

Volltextzugriff (PDF)

OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S23-S24

2021

Volltextzugriff (PDF)

Management of Complications in Multiple Myeloma

Seminars in hematology, 2009-04, Vol.46 (2), p.176-189

2009

Volltextzugriff (PDF)

Miopatía amiloidea como causa de insuficiencia respiratoria

Medicina clínica, 2016-03, Vol.146 (5), p.e25-e26

2016

Volltextzugriff (PDF)

Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma

British journal of haematology, 2005-09, Vol.130 (5), p.729-732

2005

Volltextzugriff (PDF)

Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma

European journal of haematology, 2006-01, Vol.76 (1), p.83-85

2006

Volltextzugriff (PDF)

Técnicas paramétricas de caracterización tisular del miocardio mediante resonancia magnética (parte 2): mapas de T2

Radiología, 2015-11, Vol.57 (6), p.471-479

2015

Volltextzugriff (PDF)

Dermatomyositis associated with acute myeloid leukaemia: a paraneoplastic association or a drug-induced phenomenon?

Acta dermato-venereologica, 2004, Vol.84 (5), p.401

2004

Volltextzugriff (PDF)

Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation

Annals of hematology, 2003-02, Vol.82 (2), p.131-135

2003

Volltextzugriff (PDF)

A139 Results of ASCT in 34 Patients with Amyloidosis from a Single Center

Clinical lymphoma & myeloma, 2009-02, Vol.9, p.S23-S23

2009

Volltextzugriff (PDF)

Bortezomib-induced severe hepatitis in multiple myeloma: a case report

Archives of internal medicine (1960), 2005-02, Vol.165 (4), p.464

2005

Volltextzugriff (PDF)

A160 Thalidomide/Dexamethasone (TD) Versus Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Versus VB

Clinical lymphoma & myeloma, 2009-02, Vol.9, p.S26-S26

2009

Volltextzugriff (PDF)

A154 Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly

Clinical lymphoma & myeloma, 2009-02, Vol.9, p.S25-S25

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Extramedullary multiple myeloma escapes the effect of thalidomide

Bortezomib: A valuable new antineoplastic strategy in multiple myeloma

Response to thalidomide in multiple myeloma: impact of angiogenic factors

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

P-124: The history of survival improvement in patients with Multiple Myeloma through real-world data in a 45-year period at a single institution

P-179: Immunoparesis remains a negative prognostic factor in newly diagnosed Multiple Myeloma by competing risk analysis

P-169: Outcome of non-transplant eligible patients with newly diagnosed multiple myeloma depending on the eligibility for clinical trials: a single institution experience

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p

Bortezomib: an effective agent in extramedullary disease in multiple myeloma

P-032: Clinical characteristics and outcome of 30 patients with poems syndrome in Catalonia: impact of autologous stem cell transplantation in first line and at relapse

OAB-038: Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival

P-008: First report of a patient with systemic light chain amyloidosis in the course of Multiple Myeloma treated with CAR T cells directed against B-cell maturation antigen

OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Management of Complications in Multiple Myeloma

Miopatía amiloidea como causa de insuficiencia respiratoria

Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma

Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma

Técnicas paramétricas de caracterización tisular del miocardio mediante resonancia magnética (parte 2): mapas de T2

Dermatomyositis associated with acute myeloid leukaemia: a paraneoplastic association or a drug-induced phenomenon?

Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation

A139 Results of ASCT in 34 Patients with Amyloidosis from a Single Center

Bortezomib-induced severe hepatitis in multiple myeloma: a case report

A160 Thalidomide/Dexamethasone (TD) Versus Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Versus VB

A154 Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly

Suchergebnisse filtern